Methods and compositions for decreasing T-cell activity

Details Methods and compositions for decreasing T-cell activity Methods and compositions for decreasing T-cell activity

2011-06-21

2011-06-21

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S085100, C424S085400, C424S139100, C530S351000, C530S387100

Reexamination Certificate

active

07964190

ABSTRACT:
The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4444887 (1984-04-01), Hoffmann
patent: 4474893 (1984-10-01), Reading
patent: 4714681 (1987-12-01), Reading
patent: 4716111 (1987-12-01), Osband et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4925648 (1990-05-01), Hansen et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4946788 (1990-08-01), Delespesse
patent: 5225539 (1993-07-01), Winter
patent: 5258498 (1993-11-01), Huston et al.
patent: 5349052 (1994-09-01), Delgado et al.
patent: 5474981 (1995-12-01), Leder et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5573920 (1996-11-01), Randle
patent: 5585089 (1996-12-01), Queen et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5811097 (1998-09-01), Allison et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6635743 (2003-10-01), Ebner et al.
patent: 2045869 (1991-12-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 242 233 (1987-10-01), None
patent: 0 282 317 (1988-09-01), None
patent: 0 399 816 (1990-11-01), None
patent: 0 401 384 (1990-12-01), None
patent: 0 439 095 (1991-07-01), None
patent: 0 506 477 (1992-09-01), None
patent: 0 519 596 (1992-12-01), None
patent: 0 592 106 (1994-04-01), None
patent: 0 682 110 (1995-11-01), None
patent: 0 897 114 (1999-02-01), None
patent: 8-191204 (1996-07-01), None
patent: 8-211695 (1996-08-01), None
patent: 9-019330 (1997-01-01), None
patent: 10-271997 (1998-10-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 92/05793 (1992-04-01), None
patent: WO 92/06194 (1992-04-01), None
patent: WO 92/08602 (1992-05-01), None
patent: WO 92/22324 (1992-12-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/21232 (1993-10-01), None
patent: WO 95/06058 (1995-03-01), None
patent: WO 96/14328 (1996-05-01), None
patent: WO 96/26736 (1996-09-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34095 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 96/36720 (1996-11-01), None
patent: WO 96/39515 (1996-12-01), None
patent: WO 97/33899 (1997-09-01), None
patent: WO 97/33904 (1997-09-01), None
patent: WO 97/34911 (1997-09-01), None
patent: WO 97/41831 (1997-11-01), None
patent: WO 98/02543 (1998-01-01), None
patent: WO 98/03648 (1998-01-01), None
patent: WO 98/06842 (1998-02-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/07880 (1998-02-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/25967 (1998-06-01), None
patent: WO 98/28424 (1998-07-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/30693 (1998-07-01), None
patent: WO 98/30694 (1998-07-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46645 (1998-10-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 98/54202 (1998-12-01), None
patent: WO 98/54323 (1998-12-01), None
patent: WO 98/56892 (1998-12-01), None
patent: WO 99/02563 (1999-01-01), None
patent: WO 99/11662 (1999-03-01), None
patent: WO 99/35262 (1999-07-01), None
patent: WO 99/42584 (1999-08-01), None
Horwitz et al., Chronic graft-versus-host disease, 2006, Blood Reviews, vol. 20, pp. 15-27.
Bolanos-Meade et al., Novel strategies for steroid-refractory acute graft-versus-host disease, 2004, Current Opinion in Hematology, vol. 12, pp. 40-44.
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host-disease: results of a randomized trial, 2004, Transplantation, vol. 104, No. 5, pp. 1559-1564.
Daniel et a., Mapping of linear antigenic sites on the S Glycoprotein of a neurotroic murine coronavirus with synthetic peptides, 1994, Virology, vol. 202, pp. 540-549.
Lederman et al., A single amino acid substitution in a common african allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4, 1991, Molecular Immunology, vol. 28, Issue 11, pp. 1171-1181.
Li et al., beta-endorphin omission analogs: dissociation of immunoreactivity,from other biological activities, 1980, vol. 27, Issue 6, pp. 4211-3214.
Bork et al., Go hunting in sequence databases but watch out for the traps, 1996, Trends in Genetics, vol. 12, pp. 425-427.
Bork, Powers and Pitfalls in Sequence Analysis: the 70% hurdle, 2000, Genome Research, vol. 10, pp. 398-400.
Brenner, Errors in genome annotation, 1999, Trends in Genetics, vol. 15, pp. 132-132.
Doerks et al., Protein annotation: detective, work for function prediction, 1998, Trends in Genetics, vol. 14, pp. 248-250.
Ngo et al., The protein folding problem and tertiary structure prediction,1994, pp. 492-495.
Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, 2000, Trends in Biotech, vol. 18, Issue 1, pp. 34-39.
Smith et al., The challenge of genome sequence annotation or “the devil is in the details”, 1997, Nature Biotechnology, vol. 15, pp. 1222-1223.
Wells et al., Addivity of mutational effects in proteins, 1990, Biochemistry, vol. 29, pp. 8509-8517.
Schneider et al., Lymphotoxin and LIGHT signaling pathways and target genes, 2004, Immunological Reviews, vol. 202, pp. 49-66.
Tamada et al., Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway, 2000, Nature Medicine, vol. 6, pp. 283-289.
Aggarwal, B.B, and Natarajan, K., “Tumor necrosis factors: Developments during the last decade,”Eur. Cytokine Netw. 7:93-124, John Libbey (Apr./Jun. 1996).
Anderson, D., et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,”Nature390:175-179, Macmillan Publishers, Ltd. (Nov. 1997).
Armitage, R.J., “Tumor necrosis factor receptor superfamily members and their ligands,”Curr. Opin. Immunol. 6:407-413, Current Biology, Ltd. (1994).
Baens, M., et al., “Construction and Evaluation of a hncDNA Library of Human 12p Transcribed Sequences Derived from a Somatic Cell Hybrid,”Genomics16:214-218, Academic Press, Inc. (1993).
Barton, G.J., “Protein sequence alignment and database scanning,” inProtein Structure Prediction, A Practical Approach, Sternberg, M.J.E., ed., IRL Press, Oxford, UK, pp. 31-63 (1996).
Bart{dot over (u)}n{hacek over (e)}k, P., et al., “Avian Stem Cell Factor (SCF): Production and Characterization of the Recombinant HIS-tagged SCH of Chicken and its Neutralizing Antibody,”Cytokine8:14-20, Academic Press, Inc. (Jan. 1996).
Better, M., et al., “Escherichia coliSecretion of an Active Chimeric Antibody Fragment,” Science 240:1041-1043, American Association for the Advancement of Science (1988).
Beutler, B., and Cerami, A., “Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator,”Ann. Rev. Biochem. 57:505-518, Annual Reviews, Inc. (1988).
Bird, R.E., et al., “Single-Chain Antigen-Binding Proteins,”Science242:423-426, American Association for the Advancement of Science (1988).
Blazar, B.R., et al., “In Vivo

Affiliated with

Also associated with

Rating

Methods and compositions for decreasing T-cell activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for decreasing T-cell activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for decreasing T-cell activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2662921